New York City's thriving startup scene has scored another major win with Remepy's recent $136 million funding round, aimed at revolutionizing Parkinson's disease treatment. The significant investment, backed by top venture capital firms, marks a significant step forward in the development of innovative therapies for the debilitating neurological disorder. As the world grapples with the growing need for effective Parkinson's treatments, Remepy's cutting-edge approach has garnered significant attention and support from the investment community. With this substantial funding, the company is poised to accelerate its research and development efforts, bringing hope to millions of people affected by Parkinson's worldwide.
Remepy raises $136M for Parkinson's treatment — plus 5 more NYC VC deals to know The Business Journals
